MINAPHARM PHARMACEUTICALS |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 200.3 EGP | 0.00% |
|
0.00% | -8.00% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,082 | 1,044 | 987 | 1,303 | 1,822 | 2,408 |
| Enterprise Value (EV) 1 | 1,066 | 1,171 | 922 | 1,570 | 2,562 | 4,297 |
| P/E ratio | 9.29 x | 7.4 x | 3.28 x | 2.91 x | 2.88 x | -43.5 x |
| Yield | 7.67% | - | 3.36% | 2.76% | 1.89% | 0.76% |
| Capitalization / Revenue | 0.56 x | 0.51 x | 0.42 x | 0.43 x | 0.5 x | 0.62 x |
| EV / Revenue | 0.56 x | 0.57 x | 0.39 x | 0.52 x | 0.71 x | 1.1 x |
| EV / EBITDA | 3.26 x | 3.25 x | 1.48 x | 1.89 x | 2.36 x | 8.02 x |
| EV / FCF | -38.3 x | -13.7 x | 3.33 x | -10.9 x | -4.11 x | -3.25 x |
| FCF Yield | -2.61% | -7.28% | 30.1% | -9.18% | -24.3% | -30.7% |
| Price to Book | 0.82 x | 0.82 x | 0.64 x | 0.69 x | 0.55 x | 0.7 x |
| Nbr of stocks (in thousands) | 12,293 | 12,293 | 12,293 | 12,293 | 12,293 | 11,064 |
| Reference price 2 | 88.00 | 84.95 | 80.29 | 106.0 | 148.2 | 217.7 |
| Announcement Date | 03/04/19 | 18/05/20 | 31/03/21 | 31/03/22 | 30/03/23 | 07/04/24 |
1EGP in Million2EGP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1,919 | 2,051 | 2,361 | 3,005 | 3,621 | 3,892 |
| EBITDA 1 | 326.5 | 360.6 | 621.7 | 828.5 | 1,086 | 536 |
| EBIT 1 | 269.8 | 295.7 | 538.8 | 746.5 | 964.7 | 374.7 |
| Operating Margin | 14.06% | 14.42% | 22.82% | 24.84% | 26.65% | 9.63% |
| Earnings before Tax (EBT) 1 | 181.4 | 207.9 | 432 | 668.2 | 880.3 | 33.03 |
| Net income 1 | 116.4 | 141.1 | 300.8 | 466.4 | 612.7 | -31.99 |
| Net margin | 6.07% | 6.88% | 12.74% | 15.52% | 16.92% | -0.82% |
| EPS 2 | 9.469 | 11.48 | 24.47 | 36.42 | 51.41 | -5.006 |
| Free Cash Flow 1 | -27.82 | -85.2 | 277.3 | -144.1 | -622.6 | -1,320 |
| FCF margin | -1.45% | -4.15% | 11.74% | -4.79% | -17.2% | -33.92% |
| FCF Conversion (EBITDA) | - | - | 44.6% | - | - | - |
| FCF Conversion (Net income) | - | - | 92.19% | - | - | - |
| Dividend per Share 2 | 6.750 | - | 2.700 | 2.922 | 2.800 | 1.650 |
| Announcement Date | 03/04/19 | 18/05/20 | 31/03/21 | 31/03/22 | 30/03/23 | 07/04/24 |
1EGP in Million2EGP
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 126 | - | 266 | 740 | 1,889 |
| Net Cash position 1 | 15.9 | - | 65 | - | - | - |
| Leverage (Debt/EBITDA) | - | 0.3504 x | - | 0.3216 x | 0.6811 x | 3.523 x |
| Free Cash Flow 1 | -27.8 | -85.2 | 277 | -144 | -623 | -1,320 |
| ROE (net income / shareholders' equity) | 9.1% | 10.9% | 21.1% | 26.9% | 25.3% | 0.68% |
| ROA (Net income/ Total Assets) | 6.08% | 6.62% | 10.6% | 12.3% | 11.1% | 3.02% |
| Assets 1 | 1,914 | 2,131 | 2,847 | 3,793 | 5,544 | -1,059 |
| Book Value Per Share 2 | 107.0 | 104.0 | 125.0 | 153.0 | 267.0 | 309.0 |
| Cash Flow per Share 2 | 64.80 | 62.10 | 83.30 | 79.90 | 153.0 | 173.0 |
| Capex 1 | 340 | 244 | 150 | 388 | 1,160 | 1,398 |
| Capex / Sales | 17.73% | 11.9% | 6.37% | 12.91% | 32.05% | 35.92% |
| Announcement Date | 03/04/19 | 18/05/20 | 31/03/21 | 31/03/22 | 30/03/23 | 07/04/24 |
1EGP in Million2EGP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -8.00% | 47.29M | |
| +21.28% | 44.4B | |
| +24.60% | 23.03B | |
| +19.22% | 15.14B | |
| +12.87% | 13.12B | |
| +44.67% | 11.85B | |
| -8.33% | 6.99B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +13.07% | 5.52B |
- Stock Market
- Equities
- MIPH Stock
- Financials MINAPHARM Pharmaceuticals